急性严重胆固醇性肝炎和淋巴衰竭是儿科肝炎相关的无形性贫血的特征
Daniel Tegtmeyer1,2,3, Sofia Tsaka4, Kai Lehmberg3,5
1Department of Pediatric Nephrology, Hepatology and Transplantation, University Children's Hospital, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Journal of pediatric gastroenterology and nutrition
|December 9, 2025
概括
在儿童中,肝炎相关的无形性贫血 (HAAA) 经常跟随严重的肝炎,并可能导致骨髓衰竭. 早期淋巴缺血是儿童患者HAAA的关键诊断指标.
科学领域:
- 儿科血液学 儿科血液学
- 肝病学 肝病学是一种肝病学.
- 骨髓衰竭综合征 骨髓衰竭综合征
背景情况:
- 肝炎相关无形性贫血 (HAAA) 是一种严重的疾病,其特征是源不明的急性肝炎,其次是骨髓衰竭 (BMF).
- 了解儿科HAAA对于及时诊断和管理至关重要.
研究的目的:
- 提供关于儿科HAAA的全面概述.
- 确定HAAA儿童的关键临床特征,诊断标志物和疾病进展.
主要方法:
- 对被诊断患有获得的BMF的儿童进行了回顾性分析,包括严重的无质性贫血 (SAA) 和骨髓质综合征 (MDS) 类型的儿童耐火性细胞衰竭 (RCC).
- 对HAAA分队的详细评估,包括临床特征,诊断,疾病进展和已发表病例系列的数据.
主要成果:
- 这项研究包括22名患有HAAA的儿童,平均年龄为13.5岁;45%的人先前患有病毒感染.
- 在HAAA患者中,出现严重的肝炎 (ALT和胆红素升高) 和可变凝血病;18%的人患有急性肝衰竭.
- 肝脏参数通常在8.5周内正常化,并观察到早期淋巴缺血,在肝炎发作4周内显著下降.
结论:
- 在儿科患者中,HAAA可以在SAA和RCC中发生.
- 严重的急性胆固醇性肝炎与可变凝血病是HAAA的特征;肝脏恢复是常见的.
- 早期的淋巴缺血是常见的发现,可以作为HAAA的诊断标记.
相关概念视频
Immunodeficiency Diseases
1.9K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
There are three main causes of immunodeficiency...
1.9K
Pharmacokinetics in Pediatric Patients: Drug Excretion
195
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
195
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
169
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
169
Pharmacokinetics in Pediatric Patients: Drug Metabolism
176
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
176
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
231
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
231
Pharmacokinetics in Pediatric Patients: Drug Distribution
244
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
244


